Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAVINCY trial
2021-003311-26Phase 3Active
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fosaprepitant and aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Complete response in delayed phase and Complete remission in delayed phase. Started Aug 2021; status: active.
02
Drugs
fosaprepitantaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on 2021-003311-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003311-26.